linjc16/ctgov huggingface dataset:
Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the incidence of post-ERCP pancreatitis (PEP) in chronic pancreatitis (CP) patients to that in biliary disease patients, to determine whether CP patients in early clinical stage have a higher PEP incidence, and to identify the predictive and protective factors for PEP in chronic pancreatitis patients.

Detailed Description
-----------------
Analysis of patients with chronic pancreatitis (CP group) and biliary disease (BD group) in Changhai Hospital from January 2011 to May 2015 were conducted. Difference of PEP incidences between BD group and CP group, as well as between M-ANNHEIM subcategories were calculated by chi-square test or Fisher's exact test. The predictive and protective factors for PEP were investigated by univariate and multivariate analysis.

Official Title
-----------------
Changhai Hospital, the Second Military Medical University

Conditions
-----------------
Post-ERCP Acute Pancreatitis

Intervention / Treatment
-----------------
* Other: chronic pancreatitis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with an endoscope inserted to cannulate the pancreatic/biliary duct were included. Exclusion Criteria: patients in whom the papilla of Vater was not reached; patients who underwent stent removal procedures without ductal cannulation; patients in whom the intubation was failed.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CP group<br>Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc.. | Other: chronic pancreatitis<br>* patients with chronic pancreatitis<br>|
| BD group<br>Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of chronic pancreatitis patients with post-ERCP pancreatitis, diabetes mellitus, steatorrhea, previous pancreatitis, previous PEP, pancreatic divisum, jaundice, ESWL, pancreatic duct stone, drainage and minor papilla pancreatogram. |  | 8 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of biliary disease patients with post-ERCP pancreatitis, previous pancreatitis and previous PEP. |  | 2 months |
Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the HUS

Study Overview
=================
Brief Summary
-----------------
The BK virus (BKV) belongs to the Polyomaviridae family. The primary infection, generally asymptomatic, occurs during childhood. The virus then persists in latent form in the body, mainly in the epithelial cells of the kidney and urinary tract. Cellular immunosuppression favors BKV replication. It is responsible for pathologies of the renal-urinary tract such as BKV-associated nephropathy (BKVAN) in kidney transplant recipients, hemorrhagic cystitis (HC) in hematopoietic stem cell (HSC) recipients or ureteral stenosis. To date, there is no specific antiviral treatment against BKV. The management of patients is essentially symptomatic and requires a multidisciplinary approach. It is therefore necessary to identify early prognostic markers for the occurrence of CH and to develop new therapeutic strategies.

Official Title
-----------------
Role of Neutralizing Antibodies in the Prediction and Treatment of BK Virus Infection in Hematopoietic Stem Cell Allograft Patients at the Pediatric Oncology-hematology Department of the University Hospital of Strasbourg (HUS)

Conditions
-----------------
BK Virus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult patient aged 18 to 19 years Minor patient (from birth to 17 years old) HSC allograft patient managed by the pediatric oncology-hematology service of the HUS, between 01/01/2015 and 31/12/2019 Exclusion Criteria: Opposition of the patient (or parental authority holders) to participate in the study Biological resources from a patient who does not meet all inclusion criteria Patient deprived of liberty or under court protection Patient under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of the role of anti-BKV neutralizing antibodies in HSCT patients in the pediatric oncology-hematology department of the HUS |  | Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BK virus infection, Neutralizing antibodies, Hematopoietic stem cell, Polyomaviridae
Correlation Between Markers of Neuronal Injury and Cognitive Dysfunction After Coronary Artery Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the possible Correlation Between Serum Levels of Markers of Neuronal Injury and Cognitive Dysfunction after Coronary Artery Bypass Surgery.

Detailed Description
-----------------
The systemic inflammatory response after cardiac surgery may cause damage to the central nervous system and elevated markers of brain injury in peripheral blood. This event may be potentially related to the development of postoperative cognitive dysfunction (POCD), with incidences varying from 20 to 83%.

Official Title
-----------------
Study of Correlation Between Serum Levels of Markers of Neuronal Injury and Cognitive Dysfunction After Coronary Artery Bypass Graft Surgery

Conditions
-----------------
Postoperative Cognitive Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients underwent for coronary artery bypass graft surgery Exclusion Criteria: History of brain disease or dementia, other psychiatric disorders that affect cognition Lack of proficiency in Portuguese language

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score in Neuropsycological Tests | Tests for evaluation of quality of life, depressive synths and neuropsycho;logical battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive ask and recall, including processing speed. This assessment will be applied before surgery, and 3, 7,21 90 and 180 days after surgery. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Postoperative Cognitive Dysfunction, Cardiac Surgery, General Anesthesia, Neuropsychological Tests
Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
Graft-versus-host disease (GVHD) contributes substantially to transplant-related morbidity and mortality. Steroids remains first line therapy for acute GVHD but there is currently no consensus on second line therapy for those in whom steroids have been ineffective. Basiliximab has been shown to be a safe and effective immunosuppresant in the prevention and treatment of rejection after renal transplantation and its role in acute GVHD prophylaxis and treatment has been described favourably. This is a randomized control trial to investigate its efficacy and safety in the management of acute GVHD post allogeneic stem cell transplantation (SCT).

Official Title
-----------------
A Double-blind Randomized Single-center Trial of Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation.

Conditions
-----------------
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation

Intervention / Treatment
-----------------
* Drug: Basiliximab
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Grade II to IV acute GVHD after SCT Exclusion Criteria: Known allergy to basilixmab

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Basiliximab|nan|
|Drug: Placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of GVHD by Day 12 |  | 12 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration and grading of acute GVHD |  | 100 days | 
| Total dose of steroid and immunosuppresant |  | 100 days | 
| Mortality, GVHD-related and all cause |  | 100 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute graft-versus-host disease post allogeneic stem cell transplantation
Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
The overall survival (OS)of Chronic myeloid leukemia (CML) has been significantly improved since the advent of Tyrosine kinase inhibitors (TKIs) .Nevertheless, there still exists a amount of patients who has poor response or intolerance for TKI drugs( Imatinib, dasatinib, nilotinib). Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib,and it aslo has better security when compared to other TKIs(Imatinib, dasatinib, nilotinib).It will be a better chioce for CML patients.

Official Title
-----------------
Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia : A Prospective, Multi-center, Single Arm Study

Conditions
-----------------
Validity and Safety

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old, both male and female; New Diagnosed Chronic Phase Chronic Myeloid Leukemia. Within half a year after diagnosis of CML; Previous TKIs treatment was less than 2 weeks; The pregnant test of female patients was negative (within 7 days before medication before enrollment); Informed consent of the patient or his legal representative Exclusion Criteria: T315I mutation is known to exist; Rare atypical transcript types that cannot be standardized internationally; Received TKI drugs for more than 2 weeks before enrollment; Received interferon therapy for more than 3 months before enrollment; Received other anti-CML drugs (except hydroxyurea) for more than 2 weeks or surgical treatment (including hematopoietic stem cell transplantation) patients who participate in other clinical studies at the same time; patients who having had major surgery or not recovered from surgery within 4 weeks; patients who having history of malignant tumor Woman who is pregnant or nursing Eastern Cooperative Oncology Group Physical Performance Status Score (ECOG PS) > 3; Patients known to be allergic or contraindicated to the study drug (APIs and/or excipients). A clear history of neurological or psychiatric disorders, including epilepsy or dementia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MMR rates at 12 months | MMR(BCR/ABL(IS)<0.1%) at 12 months after treating | 12 monts | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VEMR rates at 4 weeks | VEMR((BCR-ABL1/ABL1≤ 40% on the International Scale) at 4weeks after treating | 4 weeks |
Comparison of Frequency of Use of Optive and Systane

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is subjectively compare duration of action between Optive and Systane.

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Drug: Optive, Systane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females > 18 years old Mild to moderate dry eye symptoms Score of at least 2 and no more than 4 on the SESOD at the initial screening visit Likely to complete all study visits and able to provide informed consent Exclusion Criteria: Current use of topical cyclosporine Known contraindications to any study medication or ingredients Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable) Ocular surgery within the past 3 months, Active ocular allergies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Optive, Systane|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Ventilator Associated Pneumonia and Late Complications of Percutaneous Tracheostomy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the incidence of ventilator associated pneumonia and late complications by comparing two different cannulas and two different percutaneous tracheostomy techniques.

Detailed Description
-----------------
This study did not generate the expectations's we've expected, therefore, the analysis was prematurely stopped...

Official Title
-----------------
The Development of Ventilator Associated Pneumonia and Late Complications of Two Different Percutaneous Tracheostomy Techniques

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Procedure: Tracheostomy
* Device: cannula with subglottic drainage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients on the intensive care unit who receive a tracheostomy. Exclusion Criteria: HIV/AIDS use of immunosuppressive with regard to the MRI-scan patients who have a pacemaker and/or who are claustrophobic

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: subglottic drainage<br>suctioning of subglottis with cannula | Procedure: Tracheostomy<br>* trachesotomy with subglottic drainage<br>Device: cannula with subglottic drainage<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Pulmonary Infection Score first week on day 0-2-4-6 and after the first week on indication. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Two weeks and three months after decannulation: Forced oscillation technique. |  | 1 year | 
| Three months after decannulation ENT-specialist control and MRI-scan to see whether there are signs or symptoms of tracheal stenosis. |  | 1 year | 
| Peri-operative complications: procedure-related complications occurring within 24 hours of the procedure. |  | 1 year | 
| Post-operative complications: divided into 'complications while cannulated' and 'late complications'. |  | 1 year | 
| - Complications while cannulated: complications occurring after 24 hours until removal of the tracheostomy tube. |  | 1 year | 
| -Late complications: complications occuring after removal of the tracheostomy tube. |  | 1 year |
Aesthetic Evaluation of Different Abutment Materials for OsseoSpeed Implants

Study Overview
=================
Brief Summary
-----------------
The objective of the study was to assess the aesthetic outcome of different abutments materials and shapes on dental implants . A set of parameters, including assessments of the mucosa and periodontal tissue , soft tissue , radiographic evaluations and clinical photographs, was used to obtain a measure of the aesthetic of implant-prosthesis rehabilitations.

Official Title
-----------------
Aesthetic Outcome of Osseospeed Implants With Three Different Abutment Materials. A Randomized Controlled Clinical Study

Conditions
-----------------
Aesthetic Evaluation, Implant Survival Rate

Intervention / Treatment
-----------------
* Behavioral: aesthetic outcome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged over 18 years dental implant rehabilitation requested at least 1 tooth missing in areas between 1.5-3.5 and 3.5-4.5 sufficient bone volume for implant placement ( length 10-15mm; diameter 2.5-4mm, bone quality between class I and III of Lekholm and Zarb). informed consensus acceptance Exclusion Criteria: systemic pathologies that represent controindication to implantology smoking (more than 10 cigarettes per day) severe bruxism untreated periodontitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: titanium 1<br>titanium abutment type 1 | Behavioral: aesthetic outcome<br> <br> |
| Active Comparator: titanium 2<br>titanium abutment type 2 | Behavioral: aesthetic outcome<br> <br> |
| Active Comparator: zirconia 1<br>zirconia abutment type 1 | Behavioral: aesthetic outcome<br> <br> |
| Active Comparator: zirconia 2<br>zirconia abutment type 2 | Behavioral: aesthetic outcome<br> <br> |
| Active Comparator: titanium nitrate<br>titanium nitrate abutment | Behavioral: aesthetic outcome<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| aesthetic evaluation | measure of how the implant-prosthesis restoration is able to comply with the color, shape and proportions imitating as much as possible natural dentition. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| implant survival rate | Survival rate means the success rate of the dental implant and/or the restoration that is placed on top of the dental implant. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dental implant, aesthetic, implant abutment
Characterization and Differential Diagnosis of Postneurosurgical Meningitis

Study Overview
=================
Brief Summary
-----------------
Meningitis is a rare complication following neurosurgical procedures and is associated with high morbidity and mortality. The aim of this study is to describe the clinical characteristics and microbiological characteristics in patients who develope meningitis following neurosurgical operations, and investigate the useful tips for the differential diagnosis of postneurosurgical meningitis.

Detailed Description
-----------------
Besides description of characteristics of patients with postneurosurgical patients, we also will investigate the usefulness of prolonged cerebrospinal fluid (CSF) culture, and profiles of blood and CSF inflammatory markers for the differential diagnosis of meningitis. CSF culture will be extended upto 2 weeks. Serum procalcitonin and C-reactive protein, CSF adenosine deaminase levels will be monitored and analyzed for the differential diagnosis of meningitis.

Official Title
-----------------
Clinical Features, Microbiological Characteristics, and Differential Diagnosis of Postneurosurgical Meningitis

Conditions
-----------------
Neurosurgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebrospinal fluid corrected WBC >6/mm^3 and/or fever (> 38℃) and/or neck stiffness Exclusion Criteria: Patients already treated more than 48 hours for meningitis before cerebrospinal fluid examination

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of meningitis |  | within 4 weeks after neurosurgical operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | within 4 weeks after the diagnosis of meningitis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Meningitis, infection, cerebrospinal fluid, procalcitonin, adenosine deaminase